Ads
related to: cancer, pharmaceuticals- Dosing & Administration
Learn about dosing and
administration now
- Mechanism of Action
Learn about the MOA
of a new treatment option
- Dosing & Administration
Search results
Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030
Motley Fool via Yahoo Finance· 8 hours agoLilly's market cap is $767 billion, while Novo Nordisk's is $447 billion. Does one of these ...
AstraZeneca immunotherapy extends survival by two years in rarer type of lung cancer
BioPharma Dive via Yahoo Finance· 13 hours agoAstraZeneca’s immunotherapy Imfinzi helped people in the early stages of a type of lung cancer live...
FDA prioritizes review of Jazz Pharmaceuticals' new cancer therapy By Investing.com
Investing.com· 4 days agoJazz Pharmaceuticals (NASDAQ:JAZZ) announced that the U.S. Food and Drug Administration (FDA) has...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 9 hours agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow... HER2-Positive Biliary Tract ...
WLNS Lansing· 1 day agoJazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings, from the Phase 2b HERIZON-BTC ...
With new Enhertu data, an ADC could overtake chemo in breast cancer
BioPharma Dive via Yahoo Finance· 13 hours agoThe trial results are a step forward for antibody-drug conjugates, which Enhertu makers AstraZeneca...
GSK blood cancer drug nearly halves risk of death in late-stage trial
Reuters via Yahoo News· 9 hours agoGSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared...
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer - Jazz ...
Benzinga· 4 days agoTarget Action (PDUFA) Date set for November 29, 2024 If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract
... Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line...
Morningstar· 9 hours agoGilead and Arcus Announce EtrumadenantPlus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer – In Cohort B of the ARC ...
Thousands of NHS patients to trial new personalised cancer vaccine in ‘landmark moment’
The Independent via Yahoo News· 3 days agoThe scheme will work with a range of pharmaceutical companies and could expand to include patients...
Ads
related to: cancer, pharmaceuticals
